代谢紊乱中重症新型冠状病毒肺炎免疫病理生理学的见解
Insights into the Immunopathophysiology of Severe COVID-19 in Metabolic Disorders.
作者信息
Shekhar Skand, Copacino Caroline E, Barrera Francisco J, Hall Janet E, Hannah-Shmouni Fady
机构信息
Section on Endocrinology & Genetics (SEGEN), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, Maryland, USA.
Clinical Research Branch, National Institute of Environmental Health Sciences, National Institutes of Health (NIH), Research Triangle Park, North Carolina, USA.
出版信息
Ann Natl Acad Med Sci. 2020 Apr;56(2):112-115. doi: 10.1055/s-0040-1713346.
Abstract
COVID-19 has affected millions of people across the world but disproportionately and severely affects persons with metabolic disorders such as obesity, diabetes mellitus and hypertension. In this brief review, we discuss the pathways of immune dysregulation that may lead to severe COVID-19 in persons with metabolic conditions.
摘要
新型冠状病毒肺炎已影响全球数百万人，但对肥胖、糖尿病和高血压等代谢紊乱患者的影响尤为严重。在这篇简短的综述中，我们讨论了可能导致代谢疾病患者发生重症新型冠状病毒肺炎的免疫失调途径。
相似文献
1
Insights into the Immunopathophysiology of Severe COVID-19 in Metabolic Disorders.
Ann Natl Acad Med Sci. 2020 Apr;56(2):112-115. doi: 10.1055/s-0040-1713346.
2
Melatonin is a potential adjuvant to improve clinical outcomes in individuals with obesity and diabetes with coexistence of Covid-19.
Eur J Pharmacol. 2020 Sep 5;882:173329. doi: 10.1016/j.ejphar.2020.173329. Epub 2020 Jun 30.
3
Obesity, Diabetes Mellitus, and Metabolic Syndrome: Review in the Era of COVID-19.
Clin Nutr Res. 2022 Oct 24;11(4):331-346. doi: 10.7762/cnr.2022.11.4.331. eCollection 2022 Oct.
4
Immunometabolic Dysregulation at the Intersection of Obesity and COVID-19.
Front Immunol. 2021 Oct 19;12:732913. doi: 10.3389/fimmu.2021.732913. eCollection 2021.
5
The Impact of Deranged Glucose Metabolism and Diabetes in the Pathogenesis and Prognosis of the Novel SARS-CoV-2: A Systematic Review of Literature.
Curr Diabetes Rev. 2022;18(3):e060821195355. doi: 10.2174/1573399817666210806104349.
6
[The endocrine and metabolic link between COVID-19, diabetes and obesity].
Ugeskr Laeger. 2020 Jul 13;182(29).
7
Assessment of the Immune Response in Patients with Insulin Resistance, Obesity, and Diabetes to COVID-19 Vaccination.
Vaccines (Basel). 2023 Jul 5;11(7):1203. doi: 10.3390/vaccines11071203.
8
COVID-19 and metabolic disease: mechanisms and clinical management.
Lancet Diabetes Endocrinol. 2021 Nov;9(11):786-798. doi: 10.1016/S2213-8587(21)00244-8. Epub 2021 Oct 4.
9
Obesity and COVID-19: What are the Consequences?
Horm Metab Res. 2022 Aug;54(8):496-502. doi: 10.1055/a-1878-9757. Epub 2022 Jun 20.
10
Impact of Diabetes in Patients Diagnosed With COVID-19.
Front Immunol. 2020 Dec 1;11:576818. doi: 10.3389/fimmu.2020.576818. eCollection 2020.
引用本文的文献
1
Revolutionizing Treatment Strategies for Autoimmune and Inflammatory Disorders: The Impact of Dipeptidyl-Peptidase 4 Inhibitors.
J Inflamm Res. 2024 Mar 23;17:1897-1917. doi: 10.2147/JIR.S442106. eCollection 2024.
本文引用的文献
1
Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19.
N Engl J Med. 2020 Jun 18;382(25):2441-2448. doi: 10.1056/NEJMoa2008975. Epub 2020 May 1.
2
Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.
N Engl J Med. 2020 Jun 18;382(25):2431-2440. doi: 10.1056/NEJMoa2006923. Epub 2020 May 1.
3
Cytokine release syndrome in severe COVID-19.
Science. 2020 May 1;368(6490):473-474. doi: 10.1126/science.abb8925. Epub 2020 Apr 17.
4
Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.
Circ Res. 2020 Jun 5;126(12):1671-1681. doi: 10.1161/CIRCRESAHA.120.317134. Epub 2020 Apr 17.
5
Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020.
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464. doi: 10.15585/mmwr.mm6915e3.
6
Obesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital Admission.
Clin Infect Dis. 2020 Jul 28;71(15):896-897. doi: 10.1093/cid/ciaa415.
7
Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension.
Emerg Microbes Infect. 2020 Dec;9(1):757-760. doi: 10.1080/22221751.2020.1746200.
8
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor.
Nature. 2020 May;581(7807):215-220. doi: 10.1038/s41586-020-2180-5. Epub 2020 Mar 30.
9
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
10
Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection.
JCI Insight. 2019 Oct 17;4(20):131774. doi: 10.1172/jci.insight.131774.
Zotero 插件